|
|
 Previous Article | Table of Contents | Next Article 
Engraftment after infusion of CD34+ marrow cells in patients with breast
cancer or neuroblastoma
RJ Berenson, WI Bensinger, RS Hill, RG Andrews, J Garcia-Lopez, DF Kalamasz, BJ Still, G Spitzer, CD Buckner and ID Bernstein
Division of Clinical Research, Fred Hutchinson Cancer Research Center,
Seattle, WA.
The CD34 antigen is expressed by 1% to 4% of human and baboon marrow cells,
including virtually all hematopoietic progenitors detectable by in vitro
assays. Previous work from our laboratory has shown that CD34+ marrow cells
can engraft lethally irradiated baboons. Because the CD34 antigen has not
been detected on most solid tumors, positive selection of CD34+ cells may
be used to provide marrow cells capable of engraftment, but depleted of
tumor cells. In seven patients with stage IV breast cancer and two patients
with stage IV neuroblastoma, 2.5 to 17.5 x 10(9) marrow cells were
separated by immunoadsorption with the anti-CD34 antibody 12-8 and 50 to
260 x 10(6) positively selected cells were recovered that were 64 +/- 16%
(range 35% to 92%) CD34+. The patients received 1.0 to 5.2 x 10(6)
CD34-enriched cells/kg after marrow ablative therapy. Six patients
engrafted, achieving granulocyte counts of greater than 500/mm3 at 34 +/-
10 (range 21 to 47) days and platelets counts of greater than 20,000/mm3 at
46 +/- 14 (range 28 to 66) days posttransplant. Five of these patients
showed durable engraftment until the time of death 82 to 386 days
posttransplant. One patient failed to sustain engraftment associated with
metastatic marrow disease. Three patients died at days 14, 14, and 17
posttransplant, two of whom had evidence of early engraftment. These
studies suggest that CD34+ marrow cells are capable of reconstituting
hematopoiesis in humans.
Volume 77,
Issue 8,
pp. 1717-1722,
04/15/1991
Copyright © 1991 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. A. Hess, T. E. Meyerrose, L. Wirthlin, T. P. Craft, P. E. Herrbrich, M. H. Creer, and J. A. Nolta
Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity
Blood,
September 15, 2004;
104(6):
1648 - 1655.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. Hinds, J. M. Hill, E. M. Shapiro, M. O. Laukkanen, A. C. Silva, C. A. Combs, T. R. Varney, R. S. Balaban, A. P. Koretsky, and C. E. Dunbar
Highly efficient endosomal labeling of progenitor and stem cells with large magnetic particles allows magnetic resonance imaging of single cells
Blood,
August 1, 2003;
102(3):
867 - 872.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Malphettes, G. Carcelain, P. Saint-Mezard, V. Leblond, H. K. Altes, J.-P. Marolleau, P. Debre, J.-C. Brouet, J.-P. Fermand, and B. Autran
Evidence for naive T-cell repopulation despite thymus irradiation after autologous transplantation in adults with multiple myeloma: role of ex vivo CD34+ selection and age
Blood,
March 1, 2003;
101(5):
1891 - 1897.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Matsuoka, Y. Ebihara, M.-j. Xu, T. Ishii, D. Sugiyama, H. Yoshino, T. Ueda, A. Manabe, R. Tanaka, Y. Ikeda, et al.
CD34 expression on long-term repopulating hematopoietic stem cells changes during developmental stages
Blood,
January 15, 2001;
97(2):
419 - 425.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Tani, R. J. Morris, and P. Kaur
Enrichment for murine keratinocyte stem cells based on cell surface phenotype
PNAS,
September 26, 2000;
97(20):
10960 - 10965.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Lemoli, G. Martinelli, E. Zamagni, M. R. Motta, S. Rizzi, C. Terragna, R. Rondelli, S. Ronconi, A. Curti, F. Bonifazi, et al.
Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy
Blood,
April 1, 2000;
95(7):
2234 - 2239.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P Batard, M. Monier, N Fortunel, K Ducos, P Sansilvestri-Morel, T Phan, A Hatzfeld, and J. Hatzfeld
TGF-(beta)1 maintains hematopoietic immaturity by a reversible negative control of cell cycle and induces CD34 antigen up-modulation
J. Cell Sci.,
January 2, 2000;
113(3):
383 - 390.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Y. Dror and M. H. Freedman
Shwachman-Diamond Syndrome: An Inherited Preleukemic Bone Marrow Failure Disorder With Aberrant Hematopoietic Progenitors and Faulty Marrow Microenvironment
Blood,
November 1, 1999;
94(9):
3048 - 3054.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Sato, J. H. Laver, and M. Ogawa
Reversible Expression of CD34 by Murine Hematopoietic Stem Cells
Blood,
October 15, 1999;
94(8):
2548 - 2554.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. H. Cowan, J. A. Moscow, H. Huang, J. A. Zujewski, J. O'Shaughnessy, B. Sorrentino, K. Hines, C. Carter, E. Schneider, G. Cusack, et al.
Paclitaxel Chemotherapy after Autologous Stem-Cell Transplantation and Engraftment of Hematopoietic Cells Transduced with a Retrovirus Containing the Multidrug Resistance Complementary DNA (MDR1) in Metastatic Breast Cancer Patients
Clin. Cancer Res.,
July 1, 1999;
5(7):
1619 - 1628.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Moscow, H. Huang, C. Carter, K. Hines, J. Zujewski, G. Cusack, C. Chow, D. Venzon, B. Sorrentino, Y. Chiang, et al.
Engraftment of MDR1 and NeoR Gene-Transduced Hematopoietic Cells After Breast Cancer Chemotherapy
Blood,
July 1, 1999;
94(1):
52 - 61.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Mattapallil, Z. Smit-McBride, and S. Dandekar
Gastrointestinal Epithelium Is an Early Extrathymic Site for Increased Prevalence of CD34+ Progenitor Cells in Contrast to the Thymus during Primary Simian Immunodeficiency Virus Infection
J. Virol.,
May 1, 1999;
73(5):
4518 - 4523.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
C.M. Verfaillie
Adhesion Receptors as Regulators of the Hematopoietic Process
Blood,
October 15, 1998;
92(8):
2609 - 2612.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bomberger, M. Singh-Jairam, G. Rodey, A. Guerriero, A. M. Yeager, W. H. Fleming, H. K. Holland, and E. K. Waller
Lymphoid Reconstitution After Autologous PBSC Transplantation With FACS-Sorted CD34+ Hematopoietic Progenitors
Blood,
April 1, 1998;
91(7):
2588 - 2600.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Li, P. J. Simmons, and P. Kaur
Identification and isolation of candidate human keratinocyte stem cells based on cell surface phenotype
PNAS,
March 31, 1998;
95(7):
3902 - 3907.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. McSweeney, K. A. Rouleau, P. M. Wallace, B. Bruno, R. G. Andrews, L. Krizanac-Bengez, B. M. Sandmaier, R. Storb, E. Wayner, and R. A. Nash
Characterization of Monoclonal Antibodies That Recognize Canine CD34
Blood,
March 15, 1998;
91(6):
1977 - 1986.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C.-T. Hu and S. L. Chien
The Cytoplasmic Domain of Stem Cell Antigen CD34 Is Essential for Cytoadhesion Signaling But Not Sufficient for Proliferation Signaling
Blood,
February 15, 1998;
91(4):
1152 - 1162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Miltenyi
CD34+ Selection: The Basic Component for Graft Engineering
Oncologist,
December 1, 1997;
2(6):
410 - 413.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Lopez, F.M. Lemoine, H. Firat, L. Fouillard, J.P. Laporte, S. Lesage, F. Isnard, J. Stachowiak, F. Ferrer-Le Coeur, P. Morel, et al.
Bone Marrow Versus Peripheral Blood Progenitor Cells CD34 Selection in Patients With Non-Hodgkin's Lymphomas: Different Levels of Tumor Cell Reduction. Implications for Autografting
Blood,
October 1, 1997;
90(7):
2830 - 2838.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Conneally, J. Cashman, A. Petzer, and C. Eaves
Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabetic-scid/scid mice
PNAS,
September 2, 1997;
94(18):
9836 - 9841.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. G. Andrews, A. Winkler, J. Potter, E. Bryant, G. H. Knitter, I. D. Bernstein, and H. D. Ochs
Normal Immunologic Response to a Neoantigen, Bacteriophage Phi X-174, in Baboons With Long-Term Lymphohematopoietic Reconstitution From Highly Purified CD34+ Lin- Allogeneic Marrow Cells
Blood,
August 15, 1997;
90(4):
1701 - 1708.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L.B. To, D.N. Haylock, P.J. Simmons, and C.A. Juttner
The Biology and Clinical Uses of Blood Stem Cells
Blood,
April 1, 1997;
89(7):
2233 - 2258.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. G. Hanania, R. E. Giles, J. Kavanagh, D. Ellerson, Z. Zu, T. Wang, Y. Su, A. Kudelka, Z. Rahman, F. Holmes, et al.
Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy
PNAS,
December 24, 1996;
93(26):
15346 - 15351.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Dunbar and A. W. Nienhuis
Multiple Myeloma: New Approaches to Therapy
JAMA,
May 12, 1993;
269(18):
2412 - 2416.
[Abstract]
[PDF]
|
|
|
|
|
|
|
W. Anderson
Human gene therapy
Science,
May 8, 1992;
256(5058):
808 - 813.
[Abstract]
[PDF]
|
|
|
|
|
